P. Wheatley‐Price

R. Feld, Q. Chu, P. Wheatley‐Price, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy

G. Nicholas, P. Wheatley‐Price, Tinghua Zhang, 2015, Lung cancer international.

The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer

R. Vandermeer, F. Shepherd, E. Spackman, 2022, Therapeutic advances in medical oncology.

Closing the Gaps to Timely Patient Access: Perspectives on Conditional Funding Models

Eva G. Villalba, P. Wheatley‐Price, Eva Villalba, 2022, Current oncology.

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

L. Chow, A. Bardia, F. Cardoso, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.

Keunchil Park, N. Rizvi, J. Mazières, 2020, Lung cancer.

Assessment of Patient Satisfaction Among Cancer Patients Undergoing Radiotherapy

P. Wheatley‐Price, R. Samant, K. Balchin, 2021, Journal of Cancer Education.

Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer.

S. Gadgeel, Toshiaki Takahashi, P. Wheatley‐Price, 2019, Clinical Lung Cancer.

A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies

A. Tinker, K. Gelmon, L. Seymour, 2020, Investigational New Drugs.

The Diminishing Importance of Primary Site Identification in Cancer of Unknown Primary: A Canadian Single-Center Experience

P. Wheatley‐Price, M. Vickers, Boaz Wong, 2021, Frontiers in Oncology.

Thymic epithelial neoplasms: a 12-year Canadian regional cancer program experience.

M. Gomes, D. Jonker, F. Shamji, 2014, Clinical lung cancer.

Challenges of Immunotherapy in Stage IV Non-Small-Cell Lung Cancer.

P. Wheatley‐Price, K. Jao, S. Stock-Martineau, 2021, JCO oncology practice.

Chemotherapy in recurrent advanced non-small-cell lung cancer after adjuvant chemotherapy.

G. Nicholas, P. Wheatley‐Price, G. Goss, 2016, Current oncology.

Complex Germline K757N Mutation in Non-Small-Cell Lung Cancer: A Case Report

P. Wheatley‐Price, S. Moore, Boaz Wong, 2022, Case Reports in Oncology.

Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.

L. Seymour, K. Ding, F. Shepherd, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinoma

D. Christiani, A. Zhu, D. Ryan, 2008, Cancer.

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.

L. Chow, A. Bardia, N. Harbeck, 2018, The Lancet. Oncology.

Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib

L. Chow, A. Bardia, N. Harbeck, 2021 .

Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials.

P. Neven, D. Slamon, S. Chia, 2020 .

The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.

M. Tsao, Geoffrey Liu, N. Leighl, 2021, Lung cancer.

Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting.

G. Dranitsaris, M. Clemons, P. Wheatley‐Price, 2012, Current oncology.

Canadian Consensus Recommendations on the Management of MET-Altered NSCLC

N. Leighl, Q. Chu, P. Wheatley‐Price, 2021, Current oncology.

Standardizing biomarker testing for Canadian patients with advanced lung cancer.

M. Tsao, C. Couture, S. Kamel‐Reid, 2018, Current oncology.

A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226.

L. Seymour, M. Tsao, D. Tu, 2020, Lung cancer.

Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.

M. Tsao, Geoffrey Liu, Wei Xu, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacogenetic and Germline Prognostic Markers of Lung Cancer

D. Cescon, F. Shepherd, Geoffrey Liu, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk

R. Heist, J. Wain, L. Su, 2008, International journal of cancer.

Brief Report: Medical Assistance in Dying in Patients With Lung Cancer

S. Moore, P. Wheatley‐Price, C. Thabet, 2022, JTO clinical and research reports.

The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer

M. Tsao, Geoffrey Liu, N. Leighl, 2021, Therapeutic advances in medical oncology.

Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-small Cell Lung Cancer

F. Shepherd, P. Wheatley‐Price, P. Wheatley-Price, 2010 .

Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes

F. Shepherd, P. Wheatley‐Price, P. Wheatley-Price, 2008, Current opinion in oncology.

OA16.02 The Economic Value of Liquid Biopsy for Genomic Profiling in Advanced Non-Small Cell Lung Cancer

R. Vandermeer, F. Shepherd, N. Leighl, 2021, Journal of Thoracic Oncology.

Targeting Angiogenesis in the Treatment of Lung Cancer

F. Shepherd, P. Wheatley‐Price, P. Wheatley-Price, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not.

G. Nicholas, P. Wheatley‐Price, Tinghua Zhang, 2016, Lung cancer.

Non-small cell lung cancer : two decades of progress

P. Wheatley‐Price, S. Brule, P. Wheatley-Price, 2015 .

Factors influencing a specific pathologic diagnosis of non-small-cell lung carcinoma.

F. Shepherd, H. Sekhon, Geoffrey Liu, 2013, Clinical lung cancer.

Inpatients versus outpatients with advanced non-small cell lung cancer: Characteristics and outcomes.

G. Nicholas, P. Wheatley‐Price, Tinghua Zhang, 2019, Cancer treatment and research communications.

Incidence and consequences of bone metastases in lung cancer patients

M. Clemons, C. Addison, P. Wheatley‐Price, 2013, Journal of bone oncology.

Genetic Polymorphisms and Head and Neck Cancer Outcomes: A Review

D. Cescon, I. Bairati, Geoffrey Liu, 2008, Cancer Epidemiology Biomarkers & Prevention.

The Impact of Foundation Medicine Testing on Cancer Patients: A Single Academic Centre Experience

P. Wheatley‐Price, D. Karol, B. Lo, 2021, Frontiers in Oncology.

Access to Cancer Drugs in Canada

P. Wheatley‐Price, 2022, Current Oncology.

Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada.

John J. Shin, P. Wheatley‐Price, D. Stewart, 2019, The oncologist.

Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.

L. Prentice, L. Seymour, G. Nicholas, 2019, Lung cancer.

Stereotactic Body Radiotherapy (SBRT) in Very Limited-Stage Small Cell Lung Cancer (VLS-SCLC)

P. Wheatley‐Price, S. Moore, Deborah Akurang, 2022, Current oncology.

EP03.01-016 The Canadian Small Cell Lung Cancer Database (CASCADE): Results from a Multi-Institutional Real-World Evidence Collaboration

P. Wheatley‐Price, J. Agulnik, S. Moore, 2022, Journal of Thoracic Oncology.

The Pathway for New Cancer Drug Access in Canada

P. Wheatley‐Price, W. Dempster, Johanne Chambers, 2022, Current oncology.

Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologists.

J. Pantarotto, N. Leighl, P. Wheatley‐Price, 2016, Lung cancer.

Third-line chemotherapy in small-cell lung cancer: an international analysis.

Y. Summers, N. Leighl, P. Wheatley‐Price, 2014, Clinical lung cancer.

Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3.

M. Brundage, D. Tu, W. Parulekar, 2016, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit.

R. Stephens, F. Shepherd, M. Nankivell, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Prevention and Management of Bone Metastases in Lung Cancer: A Review

F. Shepherd, M. Clemons, P. Wheatley‐Price, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

19PRibociclib + letrozole vs placebo + letrozole in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC) and a high disease burden

S. Verma, M. Campone, J. Kattan, 2017 .

Prognostic factors in the radical nonsurgical treatment of stage IIIB non-small-cell lung cancer.

J. Pantarotto, E. Sabri, P. Wheatley‐Price, 2014, Clinical lung cancer.

The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials.

R. Booton, F. Shepherd, A. Hackshaw, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

The importance of greater speed in drug development for advanced malignancies

Razelle Kurzrock, Mark Clemons, Gerald Batist, 2018, Cancer medicine.

Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer

N. Harbeck, Y. Im, D. Tripathy, 2022, Therapeutic advances in medical oncology.

The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study

M. Clemons, S. Gertler, P. Wheatley‐Price, 2013, Breast Cancer Research and Treatment.

Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting.

G. Dranitsaris, M. Clemons, P. Wheatley‐Price, 2012, The journal of supportive oncology.

The Influence of Sex on Efficacy, Adverse Events, Quality of Life, and Delivery of Treatment in National Cancer Institute of Canada Clinical Trials Group Non-small Cell Lung Cancer Chemotherapy Trials

A. Bezjak, L. Seymour, K. Ding, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The most important attribute: stakeholder perspectives on what matters most in a physician.

P. Wheatley‐Price, D. Chowdhury, K. Laurie, 2019, Current oncology.

The role of palliative chemotherapy in hospitalized patients.

P. Wheatley‐Price, C. Cripps, E. Fitzgibbon, 2014, Current oncology.

Resident preparedness in discussing prognosis in patients with advanced lung cancer

F. Shepherd, T. Panzarella, C. Massey, 2010, Supportive Care in Cancer.

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial

S. Verma, M. Campone, L. Hart, 2017, Breast Cancer Research and Treatment.

Follow-Up Imaging Guidelines for Patients with Stage III Unresectable NSCLC: Recommendations Based on the PACIFIC Trial

S. Banerji, P. Wheatley‐Price, B. Melosky, 2023, Current oncology.

EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC.

P. Wheatley‐Price, S. Moore, P. Wheatley-Price, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

In-depth gene expression analysis of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial.

A. Bardia, N. Harbeck, S. Kuemmel, 2019, Journal of Clinical Oncology.